TABLE 3.
Multivariate Logistic Regression Analysis for Factors associated with Anti-Neoplastic Agent Use during Hospital Admission that included an APCU Stay
| Chemotherapeutic agents | Hormonal agents | Targeted agents | ||||
|---|---|---|---|---|---|---|
| Odds ratio (95% CI) | P-valuea | Odds ratio (95% CI) | P-valuea | Odds ratio (95% CI) | P-valuea | |
| Age, per year | 0.98 (0.97–0.99) | <0.001 | - - | - | 0.97 (0.96–0.99) | <0.001 |
| Cancer types | - - | <0.001 | - - | <0.001 | - - | 0.001 |
| Hematologic | 8 (4.8–13.2) | <0.001 | 0.95 (0.3–3.7) | 0.95 | 1.6 (0.9–2.6) | 0.11 |
| Dermatologic | 4 (2.0–7.9) | <0.001 | - - | - | 1 (0.4–2.4) | 1 |
| Genitourinary | 4.4 (2.6–7.6) | <0.001 | 3.3 (1.2–9.4) | 0.024 | 0.57 (0.28–1.18) | 0.14 |
| Primary unknown | 3.5 (1.7–7.4) | <0.001 | 2.1 (0.4–10.6) | 0.37 | 0.67 (0.23–2.0) | 0.47 |
| Breast | 3.3 (1.8–5.9) | <0.001 | 11.4 (4.5–28.6) | <0.001 | 0.57 (0.3–1.2) | 0.15 |
| Endocrine | 2.1 (0.4–9.9) | 0.35 | - - | - | - - | - |
| Gynecologic | 1.8 (0.9–3.5) | 0.077 | 4.7 (1.7–13.2) | 0.003 | 0.12 (0.03–0.51) | 0.004 |
| Gastrointestinal | 1.5 (0.8–2.6) | 0.19 | 0.4 (0.08–1.9) | 0.24 | 0.32 (0.16–0.65) | 0.001 |
| Head and neck | 1.2 (0.5–2.9) | 0.69 | - - | - | 0.39 (0.14–1.1) | 0.08 |
| Respiratory | 1 (ref.) | - | 1 (ref.) | - | 1 (ref.) | - |
| Sarcoma | 0.6 (0.2–1.9) | 0.41 | - - | - | - - | - |
| CNS | 0.6 (0.08–5.0) | 0.67 | - - | - | - - | - |
| PCU only admission | 0.31 (0.19–0.51) | <0.001 | - - | - | - - | - |
| MDA Hospital admission length, per day | 1.04 (1.03–1.06) | <0.001 | 1.02 (1.0–1.05) | 0.035 | 1.03 (1.02–1.05) | <0.001 |
| APCU admission length, per day | 0.96 (0.93–0.99) | 0.01 | - - | - | 0.94 (0.90–0.98) | 0.007 |
APCU: acute palliative care unit; CI: confidence interval; CNS: Central nervous system; MDA: M. D. Anderson Cancer Center; Ref.: reference. – denotes non-significant values